Mercado fechado

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Preço em Tempo Real. Moeda em USD.
Adicionar à lista
268,35+9,76 (+3,77%)
No fechamento: 04:00PM EDT
264,00 -4,35 (-1,62%)
Pós-fechamento: 06:34PM EDT

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
https://www.vrtx.com

Setor(es)Healthcare
IndústriaBiotechnology
Funcionários Integrais3.900

Principais Executivos

NomeTítuloPagarExercidoNascido em
Dr. Jeffrey Marc Leiden M.D., Ph.D.Exec. Chairman281,98kN/A1956
Dr. Reshma Kewalramani FASN, M.D.CEO, Pres & Director4,27MN/A1973
Mr. Charles F. Wagner Jr.Exec. VP & CFO1,85MN/A1968
Mr. Stuart A. Arbuckle B.Sc.Exec. VP & COO2,56M197,69k1966
Dr. Ourania Tatsis Ph.D.Exec. VP and Chief Regulatory & Quality Officer1,33MN/A1971
Ms. Kristen C. AmbroseChief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. ServicesN/AN/A1977
Dr. David M. Altshuler M.D., Ph.D.Exec. VP of Global Research & Chief Scientific OfficerN/AN/A1965
Mr. Mike TirozziSVP and Chief Information & Data OfficerN/AN/AN/A
Mr. Michael PartridgeSr. VP of Investor RelationsN/AN/AN/A
Mr. Damian W. Wilmot Esq.Sr. VP, Chief Risk and Compliance OfficerN/AN/A1976
Os valores são a partir de 31 de dezembro de 2021, e os valores de compensação são relativos ao ano fiscal terminando naquela data. O pagamento é salário, bônus, etc. Exercido é o valor de opções exercidas durante o ano fiscal. Moeda em USD.

Descrição

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Governança Corporativa

O QualityScore de governança da ISS da Vertex Pharmaceuticals Incorporated a partir de 1 de maio de 2022 é 7. As principais pontuações para Auditoria são: 9; Conselho: 6; Direitos de Acionistas: 6; Compensação: 8.

Pontuações em governança corporativa são cortesia da Institutional Shareholder Services (ISS). As pontuações indicam a posição do decil em relação ao índice ou à região. Uma decil com pontuação 1 indica menor risco de governança, enquanto uma pontuação 10 indica um maior risco de governança.